Announcements Trials
Browse Landscape

Phase

Phase 2 58Phase 3 30Phase 1 14Phase 4 9Phase NA 7Phase 1/2 4

Status

Terminated 5Completed 4Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × exemestane × Clear all
NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed
144 enrolled 25 charts
Breast

Breast Neoplasms

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Dana-Farber Cancer Institute

Phase 1/2 Completed
41 enrolled 12 charts
Breast

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT02732119 2021-05-05

TRINITI-1

Novartis

Phase 1/2 Completed
104 enrolled 24 charts
Breast

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

AstraZeneca

Phase 1/2 Completed
127 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡